Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

12. oktober 2026 oppdatert av: AbbVie

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.

ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.

In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

285

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Blacktown, New South Wales, Australia, 2148
        • Rekruttering
        • Blacktown Hospital /ID# 282426
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Rekruttering
        • Monash Health - Monash Medical Centre - Clayton /ID# 281468
      • Melbourne, Victoria, Australia, 3000
        • Rekruttering
        • Peter MacCallum Cancer Centre. /ID# 281751
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope National Medical Center /ID# 281381
      • Irvine, California, Forente stater, 92618
        • Rekruttering
        • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
    • Colorado
      • Denver, Colorado, Forente stater, 80218
        • Rekruttering
        • Sarah Cannon Research Institute at HealthONE /ID# 278785
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago Medical Center /ID# 278295
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68198
        • Rekruttering
        • University Of Nebraska Medical Center /ID# 281020
    • Texas
      • San Antonio, Texas, Forente stater, 78229
        • Rekruttering
        • NEXT Oncology - San Antonio /ID# 278606
    • Utah
      • West Valley City, Utah, Forente stater, 84119
        • Rekruttering
        • Start Mountain Region /ID# 278609
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Next Virginia /ID# 278607
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Frankrike, 44805
        • Rekruttering
        • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
    • Rhone
      • Lyon, Rhone, Frankrike, 69373
        • Rekruttering
        • Centre Leon Berard /ID# 280575
      • Haifa, Israel, 3109601
        • Rekruttering
        • Rambam Health Care Campus /ID# 278418
      • Jerusalem, Israel, 91120
        • Rekruttering
        • Hadassah Medical Center-Hebrew University /ID# 278420
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5265601
        • Rekruttering
        • The Chaim Sheba Medical Center /ID# 278416
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-8577
        • Rekruttering
        • National Cancer Center Hospital East /ID# 278604
    • Saitama
      • Hidaka, Saitama, Japan, 350-1298
        • Rekruttering
        • Saitama Medical University International Medical Center /ID# 278437
    • Shizuoka
      • Sunto-gun, Shizuoka, Japan, 411-8777
        • Rekruttering
        • Shizuoka Cancer Center /ID# 278538
      • Lisbon, Portugal, 1649-035
        • Rekruttering
        • Unidade Local de Saude de Santa Maria /ID# 280296
      • Porto, Portugal, 4200-072
        • Rekruttering
        • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
      • Barcelona, Spania, 08035
        • Rekruttering
        • Hospital Universitari Vall d Hebron /ID# 280442
      • Madrid, Spania, 28040
        • Rekruttering
        • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
      • Madrid, Spania, 28050
        • Rekruttering
        • Hospital Universitario HM Sanchinarro /ID# 280439
    • Madrid
      • Majadahonda, Madrid, Spania, 28222
        • Rekruttering
        • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
      • Taipei, Taiwan, 112
        • Rekruttering
        • Taipei Veterans General Hospital /ID# 281349
      • Taipei, Taiwan, 100
        • Rekruttering
        • National Taiwan University Hospital /ID# 280701

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
  • Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.

For Parts 1-4:

- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).

For Parts 5-6:

- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

Exclusion Criteria:

  • Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • Participants with platinum refractory disease.
  • Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
  • Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.

For Parts 3-6:

  • History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.

For Parts 5-6:

- Participants who had prior allergic reaction to platinum containing compound.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1: ABBV-901 Dose Escalation

Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Eksperimentell: Part 2: ABBV-901 Optimization Dose A

Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Eksperimentell: Part 2: ABBV-901 Optimization Dose B

Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Eksperimentell: Part 2: ABBV-901 Optimization Dose C

Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Eksperimentell: Part 3: ABBV-901 + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Eksperimentell: Part 4: ABBV-901 + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Eksperimentell: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Eksperimentell: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants with Adverse Events (AE)
Tidsramme: Up to Approximately 3 Years

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 3 Years
Overall Response (as assessed by the investigator)
Tidsramme: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.

Up to Approximately 3 Years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response (as assessed by independent central review)
Tidsramme: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR).

Up to Approximately 3 Years
Duration of Response (DOR)
Tidsramme: Up to Approximately 3 Years

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

Up to Approximately 3 Years
Progression-free survival (PFS)
Tidsramme: Up to Approximately 3 Years

PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to Approximately 3 Years
Overall Survival (OS)
Tidsramme: Up to Approximately 3 Years

OS is defined as time from first study treatment to death due to any cause.

Up to Approximately 3 Years
Disease Control Rate
Tidsramme: Up to Approximately 3 Years

Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.

Up to Approximately 3 Years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: ABBVIE INC., AbbVie

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. november 2025

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. januar 2029

Datoer for studieregistrering

Først innsendt

2. desember 2025

Først innsendt som oppfylte QC-kriteriene

2. desember 2025

Først lagt ut (Faktiske)

12. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere